EP0183398B1 - Inhibiteurs d'enzyme transformant l'angiotensine, leur préparation et leur application comme produits pharmaceutiques - Google Patents

Inhibiteurs d'enzyme transformant l'angiotensine, leur préparation et leur application comme produits pharmaceutiques Download PDF

Info

Publication number
EP0183398B1
EP0183398B1 EP85307931A EP85307931A EP0183398B1 EP 0183398 B1 EP0183398 B1 EP 0183398B1 EP 85307931 A EP85307931 A EP 85307931A EP 85307931 A EP85307931 A EP 85307931A EP 0183398 B1 EP0183398 B1 EP 0183398B1
Authority
EP
European Patent Office
Prior art keywords
methyl
oxopropyl
mercapto
acid
hydrazinoacetic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP85307931A
Other languages
German (de)
English (en)
Other versions
EP0183398A1 (fr
Inventor
Colin Bennion
David Peter Marriott
Anthony Ronald Cook
David Hulme Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fisons Ltd
Original Assignee
Fisons Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB848430295A external-priority patent/GB8430295D0/en
Priority claimed from GB858505798A external-priority patent/GB8505798D0/en
Priority claimed from GB858512875A external-priority patent/GB8512875D0/en
Application filed by Fisons Ltd filed Critical Fisons Ltd
Priority to AT85307931T priority Critical patent/ATE42092T1/de
Publication of EP0183398A1 publication Critical patent/EP0183398A1/fr
Application granted granted Critical
Publication of EP0183398B1 publication Critical patent/EP0183398B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C243/34—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a carbon skeleton further substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/36—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to new compounds, methods for their preparation and compositions containing them.
  • angiotensin converting enzyme (ACE) inhibitors are known, e.g. from European Patent Specification Nos. 0112511 and 121830.
  • the protecting group can be any convenient protecting group conventionally used in peptide synthesis and may be removed using techniques conventionally used in peptide synthesis.
  • carboxy protecting groups which may be used are alkoxy, e.g. C1 to 6 alkoxy such as t-butyloxy, or benzyloxy groups which can be removed, for example by hydrolysis, e.g. basic hydrolysis using aqueous methanolic sodium hydroxide; or cleavage using, for example, trifluoroacetic acid; or by hydrogenation.
  • Amino-protecting groups which may be mentioned include benzyloxycarbonyl or t-butyloxycarbonyl. We prefer to use starting materials in which the carboxy groups are protected.
  • the group X may be, for example, halo, e.g. bromo or chloro.
  • the reaction may be carried out at a temperature of from 0° to 50°C.
  • the reaction may conveniently be carried out in a non-nucleophilic solvent under basic conditions, e.g. in toluene with polyvinylpyridine.
  • reaction c) the reaction is conveniently carried out in a solvent which is inert under the reaction conditions, e.g. methanol.
  • the reaction is preferably carried out under basic conditions, e.g. in the the presence of ammonia or potassium hydroxide.
  • Process d) may be carried out in the presence of an acid catalyst, e.g. aqueous hydrochloric acid, and in the presence of a protic solvent, e.g. ethanol.
  • the reaction may be carried out at an elevated temperature, e.g. 50 to 80°C.
  • the compounds of formula IV may be made by reacting hydrazine with a compound of formula VI,
  • R 4 , R 5 , R s , X, n and Y have the significances given earlier and the reactions may be carried out using conventional reaction conditions.
  • salts of the compounds offormula I include ammonium salts, alkali metal salts, e.g. sodium and potassium salts (which are preferred); alkaline earth metal salts, e.g. the calcium and magnesium salts; salts with organic bases, e.g. salts with dicyclohexylamine or N-methyl-D-glucamine; and salts with amino acids, e.g. with arginine, lysine etc.
  • Z is R 2 CH(COOH)NH-
  • salts with organic or inorganic acids may be prepared, e.g.
  • esters include alkyl C 1 to 6, e.g. ethyl, esters and esters with benzyl alcohol.
  • Z is R 2 CH(COOH)NH-and the two -COOH groups (i.e. where Y is -OH) are in different forms, e.g. where one is esterified and the other is not. More specifically we provide such compounds in which the-COOH group adjacent to the R 2 group is esterified.
  • the salts may be formed by conventional means, e.g. by reacting the free acid or free base forms of the product with one or more equivalents of the appropriate base or acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is then removed in vacuo, or by freeze-drying, or by exchanging the ions of an existing salt for another ion on a suitable ion exchange resin.
  • the esters may be made by using the appropriate starting materials in the reaction sequence given above or by esterification of the free acid.
  • Z is R 2 CH(COOH)NH- we prefer the partial structure -NHCHRCO- in formula to be part of a naturally occurring amino acid.
  • alkyl, alkoxy or substituted alkyl groups may individually be straight or branched and contain up to and including 6 carbon atoms.
  • any halogen atoms may be bromine, fluorine or preferably chlorine atoms.
  • a specific fluoroalkyl group which may be mentioned is ⁇ CF 3 .
  • Five or 6 membered heterocyclic groups which are provided include thiophenyl, furyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, pyrimidinyl or pyridyl, each of which may be fused to a benzene ring.
  • R be hydrogen or alkyl C1 to 6, e.g. methyl.
  • R 2 be benzyl or more preferably phenylethyl.
  • R 6 is methyl or more preferably hydrogen and n to be 0.
  • R is preferably hydrogen, benzoyl or alkanoyl C2 to 6, e.g. acetyl or pivaloyl.
  • Y is preferably ⁇ OH, or a salt or alkyl C1 to 6 ester thereof.
  • R 4 and R 5 may be methyl, phenyl or more preferably hydrogen.
  • the other of R 4 and R 5 may be 1- or 2-naphthyl, cyclohexyl, alkyl C1 to 4 (preferably branched), pyridyl (e.g. 2- or 3-pyridyl), thienyl (e.g. 2-thienyl), thiazolyl (e.g. thiazol-2-yl) which may be substituted by alkyl C1 to 6 (e.g.
  • phenyl optionally substituted by one or two chlorine atoms, by -CN, by phenylsulphonylamino, by another phenyl, by alkoxy C1 to 6 (e.g. methoxy), by alkyl C1 to 6 (e.g. butyl), or by hydroxy.
  • R 4 and R 5 may together form a dihydronaphthylidene, a cyclohexylidene, an adamantylidene or an optionally oxo substituted dihydroindolyl group.
  • R 4 and R 5 not to include an aryl ring in which the aryl ring contains two or three substituents other than hydrogen.
  • R 2 is phenylethyl
  • R 4 and R 6 are both hydrogen
  • R 5 is phenyl, or alkyl or cycloalkyl containing up to 6 carbon atoms, e.g. cyclohexyl, n is 0 and Y is -OH.
  • R 4 is hydrogen
  • R 5 is alkyl or cycloalkyl containing up to 6 carbon atoms, e.g. cyclohexyl, n is 0 and Y is -OH.
  • the compounds of formula I may contain one or more asymmetric carbon atoms and may therefore exhibit optical and/or diastereo isomerism.
  • Diastereoisomers may be separated using conventional techniques, e.g. chromatography or fractional crystallisation.
  • the various optical isomers may be made by separation of a racemic or other mixture of the compounds using conventional, e.g. fractional crystallisation of HPLC, techniques.
  • the desired optical isomers may be made by reaction of the appropriate optically active starting materials under conditions which will not cause racemisation.
  • the compounds of the invention are advantageous in that they are more therapeutically, produce less side effects, are longer acting, more readily absorbed, less toxic, distributed in the body tissues in a different manner or have other advantageous properties when compared to compounds of similar structure.
  • the compounds of the invention are useful because they possess pharmacological properties. In particular they inhibit angiotensin converting enzyme and thus block conversion of the decapeptide angiotension I to angiotensin II (see Example A).
  • Angiotensin II is a potent vasoconstrictor in mammals. It also stimulates aldosterone release which results in salt and fluid retention. Increased blood pressure is the physiological result of these changes.
  • Inhibitors of angiotensin converting enzyme are thus effective antihypertensive agents in a variety of animal models (see Example B) and are indicated for use clinically, for example, in patients with renovascular, malignant or essential hypertension or chronic congestive heart failure. See, for example, D. W. Cushman et al., Biochemistry 16, 5484 (1977) and E. W. Petrillo and M. A. Ondetti, Med. Res. Rev. 2 93 (1982).
  • the compounds of this invention are useful as antihypertensives in treating hypertensive mammals, including humans and they can be utilised to achieve reduction of blood pressure, e.g. in formulations containing appropriate pharmaceutically acceptable excipients, diluents or carriers.
  • the compounds of the invention can be administered (to animals or humans) in unit dosages of 5 to 500 mg generally given several times, e.g. 1 to 4 times, per day thus giving a total daily dose of from 5 to 2000 mg per day.
  • the dose will vary depending on the type and severity of disease, weight of patient and other factors which a person skilled in the art will recognise.
  • the compounds of this invention may be given in combination with other pharmaceutically active compounds, e.g. diuretics or antihypertensives.
  • the dosage of the other pharmaceutically active compound can be that conventionally used when the compound is administered on its own, but is preferably somewhat lower.
  • one of the antihypertensives of this invention effective clinically in the range e.g. 15-200 milligrams per day, can be combined at levels ranging, e.g. from 3-200 milligrams per day with the following antihypertensives and diuretics in dose ranges per day as indicated:
  • a pharmaceutical composition comprising preferably less than 80%, more preferably less than 50%, e.g. 1 to 20%, by weight of a compound of formula I, or a pharmaceutically acceptable salt or ester thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.
  • the compound may be put up as a tablet, capsule, dragee, suppository, suspension, solution, injection, implant, a topical, e.g. transdermal, preparation such as a gel, cream, ointment, aerosol or a polymer system, or an inhalation form, e.g. an aerosol or a powder formulation.
  • a topical e.g. transdermal
  • preparation such as a gel, cream, ointment, aerosol or a polymer system, or an inhalation form, e.g. an aerosol or a powder formulation.
  • compositions which are designed to be taken oesophageally and to release their contents in the gastrointestinal tract are preferred tablets which may, for example, be made by direct compression.
  • the active ingredient is mixed with one or more of modified forms of starch, calcium phosphate, a sugar e.g. lactose, microcrystalline cellulose and/or other directly compressible excipients, together with lubricant(s), e.g. stearic acid or magnesium stearate, flow aid(s), e.g. talc or colloidal silicon dioxide, and disintegrant(s), e.g. starch or the materials sold under the Trade Marks, Nymcel, Ac-Di-Sol, Explotab and Plasdone XL. Tablets are then formed by direct compression, and may be sugar or film coated e.g. with hydroxypropylmethylcellulose.
  • the active ingredient may be granulated before tabletting.
  • the active ingredient is mixed with one or more of starch, calcium phosphate, a sugar e.g. lactose, microcrystalline cellulose or other suitable excipients and granulated with a binder such as starch, pregelled starch, polyvinylpyrrolidone, gelatine, a modified gelatine, or a cellulose derivative, e.g. hydroxypropylmethylcellulose.
  • a binder such as starch, pregelled starch, polyvinylpyrrolidone, gelatine, a modified gelatine, or a cellulose derivative, e.g. hydroxypropylmethylcellulose.
  • the mass is then dried, sieved and mixed with lubricant(s), flow aid(s) and disintegrant(s), such as described in the previous paragraph. Tablets are then formed by compression of the granules, and may be sugar or film coated, e.g. with hydroxypropylmethylcellulose
  • a powder, blend or granules such as are described above as intermediates in tabletting, may be filled into a suitable, e.g. gelatine, capsule.
  • the compound may be:-
  • the compounds may be formulated in a controlled release form.
  • the compound may be dispersed, or contained in, a polymer matrix formed from, for example, ethylcellulose, hydroxypropylmethylcellulose or the product sold under the Trade Mark Eudragit.
  • the compound may be formulated as a tablet or beads which are surrounded by a semi-permeable membrane, e.g. shellac, ethylcellulose or an acrylate/ methacrylate polymer.
  • Certain of the compounds of formula I can form hydrates or solvates, e.g. with an alcohol such as ethanol or with diethyl ether or toluene.
  • Certain of the compounds of formula I i.e. those in which Z is a group HSCH 2 ⁇ , may exist in a tautomeric cyclised form of formula la, in which R, R 4 , R 5 , R s , n and Y are as defined above.
  • the product retained a trace of toluene of crystallisation.
  • step a) A solution of the product of step a) (3.0 g) in trifluoroacetic acid (10 ml) was stirred at room temperature for 2 hours. The mixture was evaporated to an oil. and the residue purified by flash chromatography to give the sub-title compound as the free acid (2.49 g) in the form of a gum.
  • the method is based upon that of Cushman and Cheung (1971) but uses a radioactive substrate [glycine-1-'4C] hippuryl-L-histidyl-L-leucine (HHL) whose hydrolysis may be determined by liquid scintillation counting of released [ 14 C]-hippuric acid.
  • Hydrolysis of 2 mM HHL by an extract of rabbit lung acetone powder (Sigma) over a 30 min incubation period at 37° is followed by acidification of the reaction mixture and extraction of [ 14 C]hippurate with ethyl acetate.
  • SHR conscious spontaneously hypertensive rats
  • Systolic blood pressure and heart rate were measured by the tail cuff method using an electrosphygmomanometer 1 hour before and 1, 3, 5 and 24 hours after oral dosing with the compound (dose range 0.1-100 mg/kg p.o.). Percentage changes in each parameter were measured with respect to pretreatment control values.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (10)

1. Procédé de préparation d'un composé de formule I,
Figure imgb0082
où
Z représente un radical R2CH(COOH)NH- ou R1SCH2―,
R1 représente un atome d'hydrogène ou radical R8CO―,
R8 représente un radical alcoyle en C1 à 10 ou phényle,
R représente un atome d'hydrogène ou radical alcoyle en C1 à 10,
R2 représente un radical alcoyle en C1 à 10 ou phénylalcoyle en C7 à 12,
R4 et R5 qui peuvent être identiques ou différents, représentent chacun un atome d'hydrogène ou radical phényle ou naphtyle; un radical alicyclique ou hétérocyclique qui compte 5 ou 6 chaînons et dont chacun est facultativement condensé sur un cycle benzène; un radical cycloalcoyle comptant 3 à 7 atomes de carbone; ou un radical alcoyle en C1 à 10 facultativement substitué par un radical phényle ou naphtyle ou un radical hétérocyclique de 5 ou 6 chaînons, lequel dernier est facultativement condensé sur un cycle benzène,
le radical phényle, naphtyle ou alicyclique ou hétérocyclique de 5 ou 6 chaînons (lesquels deux derniers sont facultativement condensés sur un cycle benzène) sont tous facultativement substitués par un ou plusieurs radicaux alcoyle en C1 à 10, alcoxy en C1 à 10, halogéno, phénylalcoyle en C7 à 12, phénylalcoxy en C7 à 12, phényle, hydroxyle, =O, fluoroalcoyle en C1 à 10, cyano, nitro, phénylsulfonamido, dialcoyl- (en C1 à 10)-amino-alcoxy (en C1 à 10), alcoylthio en C1 à 10 ou dialcoyl- (en C1 à 10)-amino, ou bien R4 et R5 forment ensemble une chaîne
Figure imgb0083
Figure imgb0084
R6 représente un atome d'hydrogène ou radical alcoyle en C1 à 10,
q représente 2 ou 3,
n représente 0 ou 1,
Y représente un radical hydroxyle ou ―NHSO2R9, et
Rg représente un radical alcoyle en C1 à 10,
et des sels, esters et amides pharmaceutiquement acceptables de ce composé, qui comprend
a) l'élimination d'un radical protecteur d'un composé de formule I dans lequel un ou plusieurs des radicaux amino ou acide carboxylique sont protégés,
b) la réaction d'un dérivé protégé d'un composé de formule II,
Figure imgb0085
où
Z et R sont tels que définis ci-dessus, et
X représente un bon radical partant, avec un composé de formule III,
Figure imgb0086
ou un sel, ester ou dérivé protégé de celui-ci, où R4, Rs, R6, n et Y sont tels que définis ci-dessus,
c) la préparation d'un composé de formule I où R1 représente un atome d'hydrogène par scission sélective d'un composé correspondant de formule I où R1 représente un radical R8CO―, ou
d) la réaction d'un composé de formule VII,
Figure imgb0087
où Z, R, Rs, n et Y sont tels que définis ci-dessus, avec un composé de formule VIII,
Figure imgb0088
où R4 et R5 sont tels que définis ci-dessus, et lorsque la chose est souhaitée ou nécessaire, la déprotection du composé résultant ou la conversion d'un composé de formule I en un sel, ester ou amide pharmaceutiquement acceptable de celui-ci ou réciproquement.
2. Procédé suivant la revendication 1, dans lequel Z représente un radical R2CH(COOH)NH- ou R1SCH2―, n représente 0, Y représente un radical -OH, R représente un atome d'hydrogène ou radical méthyle, R6 représente un atome d'hydrogène ou radical méthyle et R2 représente un radical benzyle ou phényléthyle ou bien R1 représente un atome d'hydrogène ou radical benzoyle, acétyle ou pivaloyle.
3. Procédé suivant la revendication 1 ou 2, dans lequel l'un d'entre R4 et R5 représente un atome d'hydrogène ou radical méthyle ou phényle et l'autre représente un radical naphtyle, cyclohexyle, alcoyle en C1 à 4, pyridyle, thiényle, thiazolyle qui peut être substitué par alcoyle en C1 à 6; ou phényle facultativement substitué par un ou deux atomes de chlore, par -CN, par phénylsulfonylamino, par un autre phényle, par alcoxy en C1 à 6, par alcoyle en C1 à 6 ou par hydroxyle, ou bien où R4 et R5 forment ensemble un radical dihydronaphtylidène, un radical cyclohexylidène, un radical adamantylidène ou un radical dihydroindolyle facultativement oxo-substitué.
4. Procédé suivant l'une quelconque des revendications précédentes, dans lequel R2 représente un radical phényléthyle, R représente un radical méthyle, R4 et R6 représentent tous deux des atomes d'hydrogène, R5 représente un radical phényle ou bien alcoyle ou cycloalcoyle comptant jusqu'à 6 atomes de carbone, n représente 0 et Y représente -OH, ou bien où R1 représente un atome d'hydrogène ou R8 représente un radical phényle, R représente un radical méthyle, R4 représente un atome d'hydrogène, Rs représente un radical alcoyle ou cycloalcoyle comptant jusqu'à 6 atomes de carbone, n représente 0 et Y représente un radical -OH.
5. Procédé suivant la revendication 1, dans lequel le composé de formule est sous la forme d'un composé de formule la,
Figure imgb0089
où R, R4, R5, R6, n et Y sont tels que définis dans la revendication 1.
6. Procédé suivant la revendication 1 ou la revendication 5, dans lequel le composé de formule I ou de formule la est
l'acide (S)-1-(3-mercapto-2-méthyl-1-oxopropyl)-2-(phénylméthylène)-1-hydrazinoacétique,
le (S)-1-(3-acétylthio-2-méthyl-1-oxopropyl)-2-(phénylméthylène)-1-hydrazinoacétate d'éthyle,
l'acide (S)-1-(3-mercapto-2-méthyl-1-oxopropyl)-2-(1-naphtylméthylène)-1-hydrazinoacétique,
l'acide (S)-1-(3-mercapto-2-méthyl-1-oxopropyl)-2-(2-naphtylméthylène)-1-hydrazinoacétique,
l'acide (S)-1-(3-mercapto-2-méthyl-1-oxopropyl)-2-(3,4-dihydronaphtylidène)-1-hydrazinoacétique,
l'acide 2-[(2,6-dichlorophényl)méthylène]-1-(3-mercapto-1-oxopropyl)-1-hydrazinoacétique,
l'acide (S)-1-(3-mercapto-2-méthyl-1-oxopropyl)-2-(1-phényléthylidène)-1-hydrazinoacétique,
l'acide (S)-1-(3-mercapto-2-méthyl-1-oxopropyl)-2-(diphénylméthylidine)-1-hydrazinoacétique,
l'acide (S)-2-[(4-cyanophényl)méthylène]-1-(3-mercapto-2-méthyl-1-oxopropyl)-1-hydrazinoacétique,
l'acide (S)-2-[((4-phénylsulfonamidolphényl)méthylène]-1-(3-mercapto-2-méthyl-1-oxopropyl)-1- hydrazinoacétique,
l'acide (S)-2-cyclohexylméthylène-1-(3-mercapto-2-méthyl-1-oxopropyl)-1-hydrazinoacétique,
l'acide 2-cyclohexyl-hexahydro-6-(S)-méthyl-5-oxo-[1,3,4-thiadiazépinyl]-4-acétique,
l'acide (S)-1-(3-mercapto-2-méthyl-1-oxopropyl)-2-(2-méthylpropylidène)-1-hydrazinoacétique,
l'acide hexahydro-6-méthyl-2-(1-méthyl-éthyl)-5-oxo-[1,3,4-thiadiazépinyl]-4-acétique,
l'acide (S)-2-adamantylidene-1-(3-mercapto-2-méthyl-1-oxopropyl)-1-hydrazinoacétique,
l'acide hexahydro-6-(S)-méthyl-5-oxo-spiro[1,3,4-thiadiazépine-2,2'-tricyclo[3,3,1,13,7]décane]-4- acétique,
l'acide (S)-2-adamantylidène-1-(3-mercapto-2-méthyl-1-oxopropyl)-1-hydrazinoacétique,
l'acide hexahydro-6-(S)-méthyl-5-oxo-spiro[1,3,4-thiadiazépine-2,2'-tricyclo-[3,3,1,13,7]décane]-4- acétique,
l'acide (S)-2-[(1,1'-biphényl)-4-ylméthylène]-1-(3-mercapto-2-méthyl-1-oxopropyl)-1- hydrazinoacétique,
l'acide (S)-2-cyclohexylidène-1-(3-mercapto-2-méthyl-1-oxopropyl)-1-hydrazinoacétique,
l'acide (S)-1-(3-mercapto-2-méthyl-1-oxopropyl)-2-(2,2-diméthylpropylidène)-1-hydrazinoacétique,
l'acide (S)-2-(4-chlorophénylméthylène)-1-(3-mercapto-2-méthyl-1-oxopropyl)-1-hydrazinoacétique,
le (S)-1-(3-acétylthio-2-méthyl-1-oxopropyl)-2-(4-chlorophénylméthylène)-1-hydrazinoacétate d'éthyle,
l'acide (S)-2-[(2,6-dichlorophényl)méthylène]-1-(3-mercapto-2-méthyl-1-oxopropyl)-1- hydrazinoacétique,
l'acide (S)-2-[(2-chlorophényl)méthylène]-1-(3-mercapto-2-méthyl-1-oxopropyl)-1-hydrazinoacétique,
l'acide (S)-1-(3-mercapto-2-méthyl-1-oxopropyl)-2-[(3-pyridyl)méthylène]-1-hydrazinoacétique,
l'acide (S)-1-(3-mercapto-2-méthyl-1-oxopropyl)-2-[(2-pyridyl)méthylène]-1-hydrazinoacétique,
l'acide (S)-1-(3-mercapto-2-méthyl-1-oxopropyl)-2-[(2-thiényl)méthylène]-1-hydrazinoacétique,
l'acide (S)-1-(3-mercapto-2-méthyl-1-oxopropyl)-2-[(4-méthoxyphényl)méthylène]-1- hydrazinoacétique,
l'acide (S)-1-(3-mercapto-2-méthyl-1-oxopropyl)-2-[(4-méthylthiazol-2-yl)méthylène]-1- hydrazinoacétique,
l'acide (S)-2-[(1,1'-biphényl)-2-ylméthylène]-1-(3-mercapto-2-méthyl-1-oxopropyl)-1- hydrazinoacétique,
l'acide (S)-2-[(4-butylphényl)méthylène]-1-(3-mercapto-2-méthyl-1-oxopropyl)-1-hydrazinoacétique,
l'acide (S)-2-[(2-hydroxyphényl)méthylène]-1-(3-mercapto-2-méthyl-1-oxopropyl)-1- hydrazinoacétique,
la (S)-N-(3-mercapto-2-méthyl-1-oxopropyl)-N-(1,2-dihydro-2-oxo-3-indolylimino)glycine,
l'acide 1-[N-(1-(S)-carboxy-3-phénylpropyl)-L-alanyll-2-(phénylméthylène)-1-hydrazinoacétique,
le 1-[N-(1-(S)-éthoxycarbonyl-3-phénylpropyl)-L-alanyl]-2-(phénylméthylène)-1-hydrazinoacétate de t-butyle,
l'acide 1-[N-(1-(S)-éthoxycarbonyl-3-phénylpropyl)-L-alanyl]-2-(phénylméthylène)-1- hydrazinoacétique,
l'acide 1-[N-(1-(S)-carboxy-3-phénylpropyl)-L-alanyl]-2-(cyclohexylméthylène)-1-hydrazinoacétique,
le 2-(cyclohexylméthylène)-1-[N-(1-(S)-éthoxycarbonyl-3-phénylpropyl)-L-alanyl]-1-hydrazinoacétate de t-butyle,
l'acide 2-(cyclohexylméthylène)-1-[N-(1-(S)-éthoxycarbonyl-3-phénylpropyl)-L-alanyl]-1- hydrazinoacétique,
l'acide (S)-1-(3-benzoylthio-2-méthyl-1-oxopropyl)-2-cyclohexylméthylène-1-hydrazinoacétique,
le (S1-1-(3-benzoylthio-2-méthyl-1-oxopropyl)-2-cyclohexylméthylène-1-hydrazinoacétate de t-butyle,
l'acide 2-[1-(3-benzoylthio-1-oxopropyl)-2-(phénylméthylène)-1-hydrazino]propanoïque,
le 2-[1-(3-benzoylthio-1-oxopropyl)-2-(phénylméthylène)-1-hydrazino]propanoate de t-butyle, ou un sel pharmaceutiquement acceptable de l'un quelconque de ces composés.
7. Utilisation d'un composé de formule I ou de formule la suivant l'une quelconque des revendications 1 à 6, ou d'un sel, ester ou amide pharmaceutiquement acceptable de celui-ci, pour la préparation d'une composition pharmaceutiquement à utiliser dans le traitement d'un état d'hypertension.
EP85307931A 1984-11-30 1985-11-01 Inhibiteurs d'enzyme transformant l'angiotensine, leur préparation et leur application comme produits pharmaceutiques Expired EP0183398B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT85307931T ATE42092T1 (de) 1984-11-30 1985-11-01 Inhibitoren fuer angiotensin umwandelndes enzym, deren herstellung und verwendung als pharmazeutika.

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB8430295 1984-11-30
GB848430295A GB8430295D0 (en) 1984-11-30 1984-11-30 Biologically active nitrogen compounds
GB8505798 1985-03-06
GB858505798A GB8505798D0 (en) 1985-03-06 1985-03-06 Nitrogen containing biologically active compounds
GB8512875 1985-05-21
GB858512875A GB8512875D0 (en) 1985-05-21 1985-05-21 Nitrogen containing biologically active compounds

Publications (2)

Publication Number Publication Date
EP0183398A1 EP0183398A1 (fr) 1986-06-04
EP0183398B1 true EP0183398B1 (fr) 1989-04-12

Family

ID=27262533

Family Applications (1)

Application Number Title Priority Date Filing Date
EP85307931A Expired EP0183398B1 (fr) 1984-11-30 1985-11-01 Inhibiteurs d'enzyme transformant l'angiotensine, leur préparation et leur application comme produits pharmaceutiques

Country Status (3)

Country Link
US (1) US4748160A (fr)
EP (1) EP0183398B1 (fr)
DE (1) DE3569368D1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE71839T1 (de) * 1986-04-07 1992-02-15 Upjohn Co Anthelmintische acylhydrazone verfahren zur verwendung und zusammensetzungen.
EP0299972B1 (fr) * 1986-04-07 1992-03-04 The Upjohn Company Acylhydrazones d'alkyle quaternaire anthelmintiques, procede d'utilisation et compositions
US5025001A (en) * 1988-06-15 1991-06-18 Brigham And Women's Hospital S-nitroso derivatives of ACE inhibitors and the use thereof
US5187183A (en) * 1988-06-15 1993-02-16 Brigham & Women's Hospital S-nitroso derivatives of ACE inhibitors and the use thereof
US5356890A (en) * 1988-06-15 1994-10-18 Brigham And Women's Hospital S-nitroso derivatives of ace inhibitors and the use thereof
DE69010076T2 (de) * 1989-05-25 1994-12-08 Takeda Chemical Industries Ltd Transdermales therapeutisches Mittel.
US5811463A (en) * 1993-10-06 1998-09-22 University Of British Columbia Compositions and method for relaxing smooth muscles
US5631284A (en) * 1993-10-06 1997-05-20 University Of British Columbia Compositions and methods for relaxing smooth muscles
AU2004268707A1 (en) * 2003-08-27 2005-03-10 Merck Frosst Canada Ltd Cathepsin inhibitors
US9259535B2 (en) 2006-06-22 2016-02-16 Excelsior Medical Corporation Antiseptic cap equipped syringe
US11229746B2 (en) 2006-06-22 2022-01-25 Excelsior Medical Corporation Antiseptic cap
JP5571387B2 (ja) 2007-01-11 2014-08-13 クリティカル・アウトカム・テクノロジーズ・インコーポレイテッド 癌の治療のための化合物および方法
WO2009079797A1 (fr) * 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Composés et procédé pour le traitement du cancer
WO2010006438A1 (fr) 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Composés inhibiteurs et procédés de traitement du cancer
US9078992B2 (en) 2008-10-27 2015-07-14 Pursuit Vascular, Inc. Medical device for applying antimicrobial to proximal end of catheter
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US10166381B2 (en) 2011-05-23 2019-01-01 Excelsior Medical Corporation Antiseptic cap
ES2797649T3 (es) 2011-07-12 2020-12-03 Icu Medical Inc Dispositivo para entrega de agente antimicrobiano en un catéter transdérmico
WO2015168677A1 (fr) 2014-05-02 2015-11-05 Excelsior Medical Corporation Emballage de bande pour bouchon antiseptique
AU2016262400B2 (en) 2015-05-08 2021-01-21 Icu Medical, Inc. Medical connectors configured to receive emitters of therapeutic agents
DE102015220579A1 (de) 2015-10-21 2017-04-27 Mahle International Gmbh Stapelscheiben-Wärmeübertrager
ES2929769T3 (es) 2016-10-14 2022-12-01 Icu Medical Inc Tapas desinfectantes para conectores médicos
WO2018204206A2 (fr) 2017-05-01 2018-11-08 Icu Medical, Inc. Raccords de fluide médical et procédés pour fournir des additifs dans des conduites de fluide médical
US11541221B2 (en) 2018-11-07 2023-01-03 Icu Medical, Inc. Tubing set with antimicrobial properties
US11400195B2 (en) 2018-11-07 2022-08-02 Icu Medical, Inc. Peritoneal dialysis transfer set with antimicrobial properties
US11517732B2 (en) 2018-11-07 2022-12-06 Icu Medical, Inc. Syringe with antimicrobial properties
US11541220B2 (en) 2018-11-07 2023-01-03 Icu Medical, Inc. Needleless connector with antimicrobial properties
US11534595B2 (en) 2018-11-07 2022-12-27 Icu Medical, Inc. Device for delivering an antimicrobial composition into an infusion device
EP3883638A1 (fr) 2018-11-21 2021-09-29 ICU Medical, Inc. Dispositif antimicrobien comprenant un capuchon avec bague et insert
CA3204371A1 (fr) 2020-12-07 2022-06-16 Icu Medical, Inc. Capuchons, systemes et procedes de dialyse peritoneale

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2514219A (en) * 1949-03-30 1950-07-04 Firestone Tire & Rubber Co 1,3,6-thiadiazepine-2-thiones and their production
AT238188B (de) * 1961-07-14 1965-01-25 Hoffmann La Roche Verfahren zur Herstellung von neuen, substituierten Hydrazinverbindungen
DE1670904A1 (de) * 1967-08-10 1971-04-15 Hoechst Ag Substituierte p-Hydroxyphenylhydrazone und Verfahren zu ihrer Herstellung
US3542788A (en) * 1968-06-12 1970-11-24 Searle & Co 1-amino-5-phenyl-2-pyrrolepropionic acid and congeners
US4442038A (en) * 1982-09-17 1984-04-10 Norwich Eaton Pharmaceuticals, Inc. Converting enzyme inhibitors
US4454336A (en) * 1982-09-27 1984-06-12 American Cyanamid Company Derivatives of 3-(formylmethylthio)-propanoate
US4482544A (en) * 1982-11-29 1984-11-13 Usv Pharmaceutical Corporation Compounds for treating hypertension
GB2135299B (en) * 1983-02-14 1986-08-13 Hokko Chemical Industry & Co L Insecticidal benzoyl hydrazone derivatives
FI841052A (fi) * 1983-03-16 1984-09-17 Usv Pharma Corp Foereningar foer behandling av blodtryckssjukdomar.
EP0137746A3 (fr) * 1983-09-22 1986-01-08 FISONS plc Composés azotés substitués inhibiteurs d'enzyme de conversion d'angiotensine

Also Published As

Publication number Publication date
EP0183398A1 (fr) 1986-06-04
US4748160A (en) 1988-05-31
DE3569368D1 (en) 1989-05-18

Similar Documents

Publication Publication Date Title
EP0183398B1 (fr) Inhibiteurs d'enzyme transformant l'angiotensine, leur préparation et leur application comme produits pharmaceutiques
US4618708A (en) Amino acid derivative
FI68405C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara kaboxialkyldipeptider
US4350704A (en) Substituted acyl derivatives of octahydro-1H-indole-2-carboxylic acids
US4425333A (en) Sulfur-containing acylamino acids
SK23394A3 (en) New isosteric peptides
CZ258496A3 (en) Antithrombotic preparations
EP0037231A2 (fr) Dérivés acylés de l'acide octahydro-1H-indole-carboxylique-2
EP0217519B1 (fr) Inhibiteurs de l'enzyme de conversion de l'angiotensine hétérocycliques à 5 chaînons
HU181087B (en) Process for producing mercapto-acyl-dipeptides
US4425355A (en) Substituted acyl derivatives of chair form of octahydro-1H-indole-2-carboxylic acids
US4500467A (en) Benzoylthio compounds, their preparation and their use as drugs
US4840936A (en) Pharmaceutically useful derivatives of thiazolidine-4-carboxylic acid
KR940006770B1 (ko) 머캅토-아실아미노산 고혈압 치료제
US4587250A (en) Thiazaspirane derivatives, process for their preparation, and medicaments
CA1247085A (fr) Preparation de tripeptides renfermant la n-carboxyalcoylproline
EP0093805A1 (fr) Acides octahydro-(oméga-mercaptoalcanoyl)-2-isoindole-3-oxo-1H-carboxyliques-1 et leurs esters
US4456594A (en) N-Carboxyalkylproline-containing tripeptides
US4536501A (en) Substituted 4-phenoxy or 4-phenylthio prolines
US4634715A (en) Aza analogs of carboxyalkyl dipeptide derivatives as antihypertensives
US4503043A (en) Substituted acyl derivatives of octahydro-1H-isoindole-1-carboxylic acids
IE65539B1 (en) Trifluoromethyl mercaptan and mercaptoacyl derivatives and method of using same
EP0137746A2 (fr) Composés azotés substitués inhibiteurs d'enzyme de conversion d'angiotensine
US4897379A (en) N-[N.sup.α -(1(S)-carboxy-3-cyclohexylpropyl)-L-lysyl]-N-cyclopentylglycine as antihypertensives
JPS584770A (ja) 抗高血圧剤としてのイソキノリンカルボン酸誘導体

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19851115

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19871001

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 42092

Country of ref document: AT

Date of ref document: 19890415

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3569368

Country of ref document: DE

Date of ref document: 19890518

ITF It: translation for a ep patent filed
ET Fr: translation filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19891107

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19891109

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19891114

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19891117

Year of fee payment: 5

Ref country code: BE

Payment date: 19891117

Year of fee payment: 5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19891130

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19891130

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19891211

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19891229

Year of fee payment: 5

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19901019

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Effective date: 19901101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19901102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Effective date: 19901130

Ref country code: CH

Effective date: 19901130

Ref country code: BE

Effective date: 19901130

BERE Be: lapsed

Owner name: FISONS P.L.C.

Effective date: 19901130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19910601

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19910731

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19910801

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19911101

GBPC Gb: european patent ceased through non-payment of renewal fee
EUG Se: european patent has lapsed

Ref document number: 85307931.7

Effective date: 19910705